4D pharma today announced it registered with the SEC to list on the Nasdaq under the symbol ‘LBPS’ following its proposed merger with Longevity Acquisition. The deal is expected to close in Q1 2021, pending shareholder approval. Shareholders earlier this week voted to grant the SPAC an extension until May 2021 to close a deal. Longevity has filed a preliminary proxy on the proposed combination. Read more.
Related Posts
dMY II Updates Genius Sports Group Investor Presentation
If approved, the pro forma enterprise value of the combined company would be approximately $1.5 billion.
USA Acquisition Files for $150M IPO
USA Acquisition is broadly focused on tech firms.
Oaktree Shareholders Approve Hims & Hers Merger
The transaction is expected to close today.
SPAC bleuacacia Inks Non-Redemption Agreement
Consumer brand-focused bleuacacia raised $240 million in a November 2021 IPO.